Trade Alert - Entest BioMedical (OTCBB: ENTB) closes above $4.00

The Company put out a press release last week informing investors of updates on "Veterinary Clinic Acquisitions, Business Expansion and ImenVax(TM) Safety Study."

In the release, Entest BioMedical David Koos covered a number of updates:,

• The acquisition of McDonald Animal Hospital by ENTB was closed;
• Entest is examining two more veterinary facilities that have a combined annual revenue of $1.5 million with room for expansion."
• The McDonald facility is in the process of adding additional veterinarians, developing advertising campaigns to drive business, expanding the hours of operation and providing emergency services on weekends. Koos stated that he expects "to double the revenue at MAH over the next 18 months."
• Jennifer Hammervold is the new Director of Veterinary Practice Management. She will oversee future acquisition candidates and coordinate their integration into the Company.  
• Entest is currently recruiting dogs with cancer to participate in the ImenVax™ 10 Dog Safety Study. ImenVax™ is an immuno-therapeutic cancer vaccine being developed for dogs. Everyone involved with this research is anticipating strong results in the treatment of oral melanoma.

Since that announcement, the ENTB stock has made a steady climb to yesterday's close at $4.07.

Full Waterville Research report on ENTB.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

View the full ENTB chart at Wikinvest